Meeting
2014 ASCO Annual Meeting
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
Authors
Matthew Alexander Lunning
University of Nebraska Medical Center, Omaha, NE
Matthew Alexander Lunning , Jia Ruan , Sumithra Nair , Adam M. Boruchov , Regina Byrne , John F. Gerecitano , Paul A. Hamlin , Beth Inserra , John Leonard , Peggy Lynch , Matthew J. Matasar , Alison J. Moskowitz , Craig Moskowitz , Patricia L. Myskowski , Patrick Nolan , Maria Lia Palomba , Christiane Quefeld , David J. Straus , Andrew David Zelenetz , Steven M. Horwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT#01755975
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8582)
DOI
10.1200/jco.2014.32.15_suppl.8582
Abstract #
8582
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.
First Author: Neha Mehta-Shah
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2017 ASCO Annual Meeting
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
First Author: Geraldine Helen O'Sullivan Coyne